Products & Pipeline

Advancing Therapies for Rare Diseases

At Novelion Therapeutics, and our subsidiary Aegerion Pharmaceuticals, we are committed to advancing our portfolio by investing in science that leads to patient access for rare disease treatments.

Patient

Development Pipeline

Our Pipeline: Status of Selected Key Development Programs as of November 2016; represents ongoing phase of development; does not correspond to initiation or completion of a particular phase.

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

Aegerion Products

JUXTAPID® (lomitapide)*
homozygous familial hypercholesterolemia (HoFH) in adults
MYALEPT® (metreleptin)**
generalized lipodystrophy (GL)
metreleptin
partial lipodystrophy (PL)***

Novelion Products

zuretinol
leber congenital amaurosis (LCA)
zuretinol
retinitis pigmentosa (RP)

* Click here for JUXTAPID® (lomitapide) full US prescribing information, including BOXED WARNING for the risk of hepatotoxicity.

** Click here for MYALEPT® (metreleptin) full US prescribing information, including BOXED WARNING for the risk of anti-metreleptin antibodies with neutralizing activity and risk of lymphoma.

*** Plan to submit MAA for metreleptin in EU to treat GL and a subset of PL

For more information about our marketed products, visit: